0001731122-24-000263.txt : 20240216
0001731122-24-000263.hdr.sgml : 20240216
20240216090647
ACCESSION NUMBER: 0001731122-24-000263
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240216
DATE AS OF CHANGE: 20240216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dybul Mark
CENTRAL INDEX KEY: 0001734805
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38758
FILM NUMBER: 24645914
MAIL ADDRESS:
STREET 1: 8974 BAYVIEW DRIVE,
CITY: CHESTERTOWN
STATE: MD
ZIP: 21620
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RENOVARO INC.
CENTRAL INDEX KEY: 0001527728
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 452259340
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: CENTURY CITY MEDICAL PLAZA
STREET 2: 2080 CENTURY CITY EAST
CITY: SUITE 906 LOS ANGELES
STATE: CA
ZIP: 90067
BUSINESS PHONE: 45 39179840
MAIL ADDRESS:
STREET 1: CENTURY CITY MEDICAL PLAZA
STREET 2: 2080 CENTURY CITY EAST
CITY: SUITE 906 LOS ANGELES
STATE: CA
ZIP: 90067
FORMER COMPANY:
FORMER CONFORMED NAME: RENOVARO BIOSCIENCES INC.
DATE OF NAME CHANGE: 20230807
FORMER COMPANY:
FORMER CONFORMED NAME: Enochian Biosciences Inc.
DATE OF NAME CHANGE: 20230804
FORMER COMPANY:
FORMER CONFORMED NAME: Renovaro Biosciences Inc.
DATE OF NAME CHANGE: 20230802
4
1
ownership.xml
X0508
4
2024-02-13
0
0001527728
RENOVARO INC.
RENB
0001734805
Dybul Mark
C/O RENOVARO BIOSCIENCES INC.
9480 NE 2ND AVENUE #73
MIAMI
FL
33138
1
1
0
0
Chief Executive Officer
0
Option to Purchase Common Stock
5.95
2024-02-13
4
D
0
7563
D
2028-02-28
Common Stock
7563
0
D
Option to Purchase Common Stock
1.92
2024-02-13
4
A
0
7563
A
2024-02-13
2028-02-28
Common Stock
7563
7563
D
Option to Purchase Common Stock
5.74
2024-02-13
4
D
0
5226
D
2019-02-28
2028-09-19
Common Stock
5226
0
D
Option to Purchase Common Stock
1.92
2024-02-13
4
A
0
5226
A
2024-02-13
2028-09-19
Common Stock
5226
5226
D
Option to Purchase Common Stock
6.50
2024-02-13
4
D
0
300000
D
2018-11-21
2028-11-21
Common Stock
300000
0
D
Option to Purchase Common Stock
1.92
2024-02-13
4
A
0
300000
A
2024-02-13
2028-11-21
Common Stock
300000
300000
D
Option to Purchase Common Stock
8.00
2024-02-13
4
D
0
450000
D
2021-06-11
2031-06-11
Common Stock
450000
0
D
Option to Purchase Common Stock
1.92
2024-02-13
4
A
0
450000
A
2024-02-13
2031-06-11
Common Stock
450000
450000
D
Option to Purchase Common Stock
4.57
2024-02-13
4
D
0
2000000
D
2031-07-19
Common Stock
2000000
0
D
Option to Purchase Common Stock
1.92
2024-02-13
4
A
0
2000000
A
2031-07-19
Common Stock
2000000
2000000
D
Option to Purchase Common Stock
2.54
2024-02-13
4
D
0
350000
D
2032-08-25
Common Stock
350000
0
D
Option to Purchase Common Stock
1.92
2024-02-13
4
A
0
350000
A
2032-08-25
Common Stock
350000
350000
D
The option vested in three equal installments on February 28, 2019, February 28, 2020 and February 28, 2021.
The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options.
The option vested in two equal installments on July 1, 2022 and July 1, 2023. The remainder of the option vests on July 1, 2024.
One third of the option vested on August 25, 2023. The remainder of the option shall vest in two equal installments on August 25, 2024 and August 25, 2025.
/s/ Mark Dybul
2024-02-16